Literature DB >> 26192177

Dietary supplement implicated in fulminant hepatic failure in a well-controlled Wilson disease patient.

Kengo Kawai1, Yoshinari Atarashi1, Terumi Takahara2, Hiroshi Kudo1, Kazuto Tajiri1, Yoshiharu Tokimitsu1, Yasuhiro Nakayama1, Katsuharu Hirano1, Yutaka Yata1, Masami Minemura1, Satoshi Yasumura3, Yasuharu Onishi4, Kazuhiro Tsukada4, Koichi Tsuneyama5, Yasuo Takano5, Toshiro Sugiyama1.   

Abstract

We encountered a patient with previously well-controlled Wilson disease who experienced fulminant hepatic failure with hemolytic anemia, possibly caused by the dietary supplement Health Proportion(®) (Jubilant Co., Ltd., Ehime, Japan). A 21-year-old woman was admitted to our hospital with marked liver dysfunction and severe hemolytic anemia. Free serum copper level was elevated at 101 μg/dl, and urinary copper excretion was extremely increased (25,600 μg/day). Plasma exchange and continuous hemodiafiltration were performed to remove serum copper and to treat the hemolytic anemia. However, liver function did not improve, and she underwent liver transplantation on 28th day after admission. Copper and iron contents in the resected liver were high at 851.9 μg and 551.7 μg/dry liver weight (g), respectively, despite the patient having regularly taken D-penicillamine since diagnosis and having a well-controlled copper level 1 year before her admission. Two months before admission, the patient had taken a dietary supplement made from soybeans for 1 month. This supplement was labeled as containing large amounts of copper and iron, and we assume that this caused fulminant hepatic failure with hemolytic crisis in this patient. It is important to be mindful of the micronutrient content of dietary supplements, especially for metabolic disorder patients.

Entities:  

Keywords:  Copper; Dietary supplements; Fulminant hepatic failure; Wilson disease

Year:  2009        PMID: 26192177     DOI: 10.1007/s12328-008-0056-6

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  20 in total

1.  A practice guideline on Wilson disease.

Authors:  Eve A Roberts; Michael L Schilsky
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

2.  Plasma exchange for fulminant Wilson disease.

Authors:  J Sarles; P Lefevre; G Picon
Journal:  Eur J Pediatr       Date:  1992-04       Impact factor: 3.183

Review 3.  Genetic aspects of Wilson's disease.

Authors:  M Frydman
Journal:  J Gastroenterol Hepatol       Date:  1990 Jul-Aug       Impact factor: 4.029

4.  Chelation treatment of neurological Wilson's disease.

Authors:  J M Walshe; M Yealland
Journal:  Q J Med       Date:  1993-03

5.  Drug-induced liver injury at an Asian center: a prospective study.

Authors:  Chun-Tao Wai; Bee-Him Tan; Cheng-Leng Chan; Dede S Sutedja; Yin-Mei Lee; Christopher Khor; Seng-Gee Lim
Journal:  Liver Int       Date:  2007-05       Impact factor: 5.828

6.  Hemolytic anemia in Wilson's disease.

Authors:  N McIntyre; H M Clink; A J Levi; J N Cumings; S Sherlock
Journal:  N Engl J Med       Date:  1967-02-23       Impact factor: 91.245

7.  Novel mutations of the ATP7B gene in Japanese patients with Wilson disease.

Authors:  Y Kusuda; K Hamaguchi; T Mori; R Shin; M Seike; T Sakata
Journal:  J Hum Genet       Date:  2000       Impact factor: 3.172

8.  Cholestatic liver injury associated with whey protein and creatine supplements.

Authors:  Kerry N Whitt; Stephen C Ward; Kemal Deniz; Lawrence Liu; Joseph A Odin; Lihui Qin
Journal:  Semin Liver Dis       Date:  2008-05       Impact factor: 6.115

9.  Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver, by S. A. Kinnier Wilson, (From the National Hospital, and the Laboratory of the National Hospital, Queen Square, London) Brain 1912: 34; 295-509.

Authors:  Alastair Compston
Journal:  Brain       Date:  2009-08       Impact factor: 13.501

10.  The Wilson disease gene: spectrum of mutations and their consequences.

Authors:  G R Thomas; J R Forbes; E A Roberts; J M Walshe; D W Cox
Journal:  Nat Genet       Date:  1995-02       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.